Navigation Links
Spike in Use of Popular Reflux Drug to Treat Infants Causes Alarm
Date:5/3/2010

Reglan, metoclopramide never approved for use in infants

HOUSTON, May 3 /PRNewswire-USNewswire/ -- Recently, researchers have observed a disturbing trend in neonatal units across the country:  doctors prescribing Reglan -- also known by its generic name, metoclopramide -- to treat premature infants. This alarming development has raised serious concerns from many consumer safety advocates, particularly because the drug was never approved for use in infants.

Reglan (metoclopramide) was approved for short term use – no longer than three months – by the Food & Drug Administration in 1979 to treat various gastrointestinal disorders.  But in 2009, the FDA issued a black box warning, the strongest of its kind, for the drug and its generic forms, stating that the medication had "been linked to tardive dyskinesia."  In fact, Reglan (metoclopramide) has been identified as the leading cause of TD among patients with the disorder in the United States.

The increase in its use in neonatal units began about a decade ago, when the only motility agent approved for use in infants was pulled from the market for safety concerns.  It has continued to grow each year.  While those at highest risk of developing TD are women and the elderly, there are very serious concerns about the safety of treating babies with Reglan (metoclopramide), as there has never been any significant research done on the drug's effects on infant populations.  

"Although the FDA issued its black box warning last year," said Scott Nabers, of Blizzard, McCarthy & Nabers, which represents dozens of patients disabled by Reglan, "many doctors and patients are still not aware of the significant risks associated with its use.  Because Reglan has been on the market for over 30 years, many physicians assume the drug is safe and prescribe it for various off-label uses.  Perhaps the most troubling of these is its use to treat premature babies whose bodies are already extremely frail."

Blizzard, McCarthy & Nabers recently launched the website ReglanJustice.com to provide consumers with critical information about the risks associated with Reglan (metoclopramide).

Blizzard, McCarthy & Nabers, LLP, one of the nation's leading pharmaceutical litigation firms, represents thousands of clients harmed by dangerous drugs and medical devices and has taken on some of the world's largest corporations, including Bristol-Myers, GlaxoSmithKline, Merck, Pfizer and Dow Chemical. 


'/>"/>
SOURCE Blizzard, McCarthy & Nabers, LLP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Senate Rejects Bulk Imports of Medicine from Canada, but Personal Importation Remains a Popular Option for U.S. Citizens
2. VerifyNow(R) System Highlighted in POPular Study Comparing Platelet Reactivity Tests
3. Popular Breast Cancer Drug Used with Certain Antidepressants Puts New Jersey Women at Risk
4. Research: Popular Diabetes Medications Associated with Increase in Bone Fractures
5. New Studies Show Popular Heartburn Medications Moderate the Effect of Taking Widely Prescribed Heart Drug
6. Clinical Trial Shows Cardiovascular Benefits of Rooibos, Popular Antioxidant Herbal Tea from South Africa
7. Popular Energy Drinks Cause Tooth Erosion
8. Recent Studies Suggest Popular Diet Pill Relacore Reduces Acne Breakouts
9. An Open Letter to Parents, Students, School Administrators, & Health Care Officials from Soapopular(R)
10. New Incision-Less Procedure for REFLUX - Experts Consider it to Be Gold Standard for REFLUX
11. Medical World Recognises New Therapy for Reflux Babies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., a ... today announced that it has been ranked #1 by its ... Book™ Rankings 2017 User Survey. ZirMed was recognized as ... large hospitals and medical centers over 200 beds and holds ... healthcare technology user survey history. ...
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... agency serving communities in the greater Dallas, Miami, and Raleigh regions, is organizing ... fighting to overcome a rare and deadly chromosome abnormality. , After struggling since ...
(Date:10/13/2017)... , ... October 13, 2017 , ... While it’s often ... a problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , She ... in darkness or restricted lighting. As such, it eliminates the need to turn on ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and ... Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD ... that can be easily incorporated into liquid products, while reducing costs to end users. ...
(Date:10/13/2017)... ... , ... Apple Rehab Shelton Lakes , which specializes in the delivery ... as part of a disaster drill on October 3rd. , Apple Rehab participated with ... Manager, as well as the Connecticut Long Term Care Mutual Aid Plan (LTC-MAP). ...
(Date:10/13/2017)... ... 13, 2017 , ... Ellevate Network, the leading network for professional women, brought ... gender equality at their inaugural Summit in New York City in June. The event ... audience of over 3 million. To watch the Mobilize Women video, click here ...
Breaking Medicine News(10 mins):